Alkermes Rallies Off Positive Data For Depression Drug Trial

Alkermes Plc ALKS shares are trading higher by $14.33 at $57.81 in Friday's session. There are two catalysts that are factoring into the rally.

First of all, after the close on Thursday, the company announced positive data from a depression treatment trial. Also, the issue moved higher on positive comments from CNBC's Jim Cramer.

After a higher open, it continued in that direction until peaking at $59.40 and reversing course.

Related Link: JPMorgan Upgrades Alkermes Plc To Overweight

That level is shy of its January 20 high of $61.56. The following day the issue sank to $33.69 following the announcement that ALKS5461 study for depression disorder did not meet its endpoint.

The ensuing decline off the high has found intraday support at $54.80 and now the issue is attempting to remain at the $57 handle.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechTechnicalsIntraday UpdateMoversTrading IdeasGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!